头颈部局部晚期癌的遗传学与管理：超分割放疗的作用
Genetics and management of locally advanced carcinomas of the head and neck: role of altered fractionation radiotherapy.
作者信息
Perri Francesco, Ionna Franco, Muto Paolo, Marzo Massimiliano Di, Caponigro Francesco, Longo Francesco, Vittoria Scarpati Giuseppina Della, Lorenzo Giuseppe Di, Giuliano Mario, Solla Raffaele
机构信息
Head & Neck, Soft Tissue Sarcoma Medical Oncology Department, National Tumor Institute of Naples, IRCCS G Pascale, Napoli, Naples, Italy.
Otolaryngology Unit, Department of Head & Neck, Soft Tissue Sarcoma & Thyroid Cancer, National Tumor Institute of Naples, IRCCS G Pascale, Napoli, Naples, Italy.
出版信息
Future Sci OA. 2018 Oct 26;5(1):FSO347. doi: 10.4155/fsoa-2018-0058. eCollection 2019 Jan.
Abstract
Squamous cell carcinoma of the head and neck (SCCHN) accounts for 5-7% of all malignancies. About 60% of newly diagnosed SCCHN are detected as locally advanced disease. Chemoradiation is a standard option and response rate to it is variable. Recently, a genetic classification of SCCHN has been proposed by Chung ., who categorized all SCCHN into four subtypes. The basal-like variant is characterized by high expression of EGFR. Literature data suggest higher efficacy of accelerated and/or hyperfractionated radiotherapy, if compared with conventional radiotherapy in the subgroup of patients with high EGFR expression. In this review, we will describe the genetic factors able to guide treatment choice, with a focus on EGFR expression.
摘要
头颈部鳞状细胞癌（SCCHN）占所有恶性肿瘤的5-7%。新诊断的SCCHN中约60%被检测为局部晚期疾病。放化疗是一种标准选择，但其缓解率各不相同。最近，Chung等人提出了SCCHN的基因分类，将所有SCCHN分为四种亚型。基底样变体的特征是表皮生长因子受体（EGFR）高表达。文献数据表明，与传统放疗相比，在表皮生长因子受体高表达患者亚组中，加速和/或超分割放疗疗效更高。在本综述中，我们将描述能够指导治疗选择的遗传因素，重点是表皮生长因子受体表达。
相似文献
1
Genetics and management of locally advanced carcinomas of the head and neck: role of altered fractionation radiotherapy.头颈部局部晚期癌的遗传学与管理：超分割放疗的作用
Future Sci OA. 2018 Oct 26;5(1):FSO347. doi: 10.4155/fsoa-2018-0058. eCollection 2019 Jan.
2
A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.多西他赛与顺铂每周联合同步超分割放疗用于非小细胞肺癌及头颈部鳞状细胞癌的I期试验。
Oncol Rep. 2003 Jan-Feb;10(1):185-95. doi: 10.3892/or.10.1.185.
3
Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.对头颈部局部晚期鳞状细胞癌进行靶向二代测序可揭示用于改善辅助放化疗的可用药靶点。
Eur J Cancer. 2016 Apr;57:78-86. doi: 10.1016/j.ejca.2016.01.003. Epub 2016 Feb 18.
4
EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?表皮生长因子受体单克隆抗体在局部晚期头颈部鳞状细胞癌中的应用：其当前作用是什么？
Crit Rev Oncol Hematol. 2016 Mar;99:170-9. doi: 10.1016/j.critrevonc.2015.12.006. Epub 2015 Dec 19.
5
Translational Research: A Future Strategy for Managing Squamous Cell Carcinoma of the Head and Neck?转化研究：头颈部鳞状细胞癌管理的未来策略？
Anticancer Agents Med Chem. 2018;18(9):1220-1227. doi: 10.2174/1871520618666180411110036.
6
Evidence-based radiation oncology in head and neck squamous cell carcinoma.头颈部鳞状细胞癌的循证放射肿瘤学
Radiother Oncol. 2007 Oct;85(1):156-70. doi: 10.1016/j.radonc.2007.04.002. Epub 2007 May 4.
7
8
Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.监测局部晚期头颈部鳞状细胞癌联合放化疗过程中循环肿瘤细胞及其 EGFR/磷酸化 EGFR 的表达。
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e685-90. doi: 10.1016/j.ijrobp.2012.02.009. Epub 2012 May 12.
9
Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.在一项随机对照试验中，头颈部鳞状细胞癌预处理活检组织中的表皮生长因子受体表达作为加速放疗获益的预测因素。
J Clin Oncol. 2005 Aug 20;23(24):5560-7. doi: 10.1200/JCO.2005.06.411.
引用本文的文献
1
Prospective validation of diffusion-weighted MRI as a biomarker of tumor response and oncologic outcomes in head and neck cancer: Results from an observational biomarker pre-qualification study.前瞻性验证弥散加权 MRI 作为头颈部癌症肿瘤反应和肿瘤学结局的生物标志物：来自观察性生物标志物预认证研究的结果。
Radiother Oncol. 2023 Jun;183:109641. doi: 10.1016/j.radonc.2023.109641. Epub 2023 Mar 27.
2
CircRFWD3 promotes HNSCC metastasis by modulating miR-27a/b/PPARγ signaling.环状RFWD3通过调节miR-27a/b/PPARγ信号通路促进头颈部鳞状细胞癌转移。
Cell Death Discov. 2022 Jun 11;8(1):285. doi: 10.1038/s41420-022-01066-6.
3
Boosting the Immune Response with the Combination of Electrochemotherapy and Immunotherapy: A New Weapon for Squamous Cell Carcinoma of the Head and Neck?电化学疗法与免疫疗法联合增强免疫反应：头颈鳞状细胞癌的新武器？
Cancers (Basel). 2020 Sep 28;12(10):2781. doi: 10.3390/cancers12102781.
4
Efficacy and Safety of Intro-Arterial Chemotherapy Combined with Radiotherapy on Head and Neck Cancer: A Systematic Review and Meta-Analysis.动脉内化疗联合放疗治疗头颈癌的疗效与安全性：一项系统评价与Meta分析
J Cancer. 2019 Oct 17;10(25):6233-6243. doi: 10.7150/jca.36478. eCollection 2019.
本文引用的文献
1
Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis.标准剂量每3周一次顺铂与低剂量每周一次顺铂用于局部晚期头颈部鳞状细胞癌患者同步放化疗的比较：一项多中心回顾性分析。
Medicine (Baltimore). 2018 May;97(21):e10778. doi: 10.1097/MD.0000000000010778.
2
Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.低危型人乳头瘤病毒相关口咽鳞状细胞癌去强化放化疗的前瞻性研究的成熟结果。
Cancer. 2018 Jun 1;124(11):2347-2354. doi: 10.1002/cncr.31338. Epub 2018 Mar 26.
3
The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma.2个疗程急性毒性的比较：头颈部鳞状细胞癌患者接受放疗时每三周一次和顺铂每周一次的治疗。
Medicine (Baltimore). 2017 Dec;96(51):e9151. doi: 10.1097/MD.0000000000009151.
4
Human papillomavirus associated head and neck squamous cell carcinoma: Controversies and new concepts.人乳头瘤病毒相关头颈部鳞状细胞癌：争议与新概念
J Oral Biol Craniofac Res. 2017 Sep-Dec;7(3):198-205. doi: 10.1016/j.jobcr.2017.08.003. Epub 2017 Sep 1.
5
The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis.关于局部晚期头颈部鳞状细胞癌（HNSCC）中每周一次与每三周一次顺铂同步放疗疗效的证据：一项系统评价和荟萃分析。
Br J Radiol. 2017 Nov;90(1079):20170442. doi: 10.1259/bjr.20170442.
6
Can Intensity-Modulated-Radiotherapy Reduce Toxicity in Head and Neck Squamous Cell Carcinoma?调强放射治疗能否降低头颈部鳞状细胞癌的毒性？
Cancers (Basel). 2017 Oct 6;9(10):135. doi: 10.3390/cancers9100135.
7
[Radiotherapy for head and neck squamous cell carcinoma: State of the art and future directions].[头颈部鳞状细胞癌的放射治疗：现状与未来方向]
Cancer Radiother. 2017 Oct;21(6-7):498-504. doi: 10.1016/j.canrad.2017.07.032. Epub 2017 Aug 31.
8
Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.低剂量放疗治疗人乳头瘤病毒相关口咽鳞癌的单臂、2 期研究。
Lancet Oncol. 2017 Jun;18(6):803-811. doi: 10.1016/S1470-2045(17)30246-2. Epub 2017 Apr 20.
9
Prospective evaluation of Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost (IMRT-SIB) in head and neck squamous cell carcinoma in patients not suitable for chemo-radiotherapy.对不适宜放化疗的头颈部鳞状细胞癌患者采用调强放疗同步整合加量（IMRT-SIB）的前瞻性评估
Oral Oncol. 2017 Apr;67:10-16. doi: 10.1016/j.oraloncology.2017.01.005. Epub 2017 Jan 30.
10
Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy.基础抗体依赖的细胞介导的细胞毒性（ADCC）升高和高表皮生长因子受体（EGFR）表达预示着接受西妥昔单抗和放疗的局部晚期头颈癌患者预后良好。
Cancer Immunol Immunother. 2017 May;66(5):573-579. doi: 10.1007/s00262-017-1960-8. Epub 2017 Feb 14.
Zotero 插件